ESMO Breast 2023 | Is it possible to predict who will benefit the most from IO in TNBC?

Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, provides an overview of the most popular biomarkers currently utilized for predicting a patient’s prognosis following immunotherapy (IO) for triple-negative breast cancer (TNBC). Dr Balko discusses the functionality of PD-L1 expression, tumor mutation burden, tumor infiltrating lymphocytes (TIL) and novel prognostic biomarkers such as tumor microenvironment antigen presentation as indicators of immunotherapy efficacy. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.